Marinus Pharmaceuticals Provides Business Update and 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Jefferies Cuts Price Target on Marinus Pharma (MRNS) to $13 Following 4Q
March 8, 2016 8:34 AM ESTJefferies maintained a Buy rating on Marinus Pharmaceuticals (NASDAQ: MRNS), and cut the price target to $13.00 (from $14.00), following the company's 4Q. Total operating expenses for Q4 were $7.5M consisting of $6.1M of R&D and $1.4M G&A expense. MRNS is set to announce... More
Marinus Pharma (MRNS) Reports Q4 Loss of $0.45
March 7, 2016 7:35 AM ESTMarinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.45), versus ($0.26) reported last year.
For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.
... More